Prohost Letters
Premium
Prohost Letter #410
Prohost Letter #410 JUNE PDUFA DAYS This month, the FDA will decide on the approvals of drugs belonging to companies that Prohost has picked for investment. Usually, granting approvals rallies the sto...
P
Prohost Biotech
1 min read
11
0
Unlock Premium Content
This article contains exclusive content for our premium subscribers. Join our community to access in-depth research, expert insights, and comprehensive analysis.
Unlimited articles
Expert analysis
Research reports
Tags
American Society of Clinical Oncology (ASCO)
Array BioPharma (ARRY)
Biogen Inc (BIIB)
bluebird bio Inc (BLUE)
Bristol-Myers Squibb (BMY)
CAR-T
Celyad (CYAD)
Epizyme Inc (EPZM)
Exelixis (EXEL)
Genentech
Halozyme Therapeutics (HALO)
ImmunoGen (IMGN)
Incyte (INCY)
Juno Therapeutics (JUNO)
Kite Pharma - A Gilead Company
Loxo Oncology Inc (LOXO)
Merck (MRK)
Newlink Genetics (NLNK)
Portola Pharmaceuticals Inc (PTLA)
Prescription Drug User Fee Act (PDUFA)
Prohost Portfolio
Roche (RHHBY)
Spark Therapeutics
Syndax Pharmaceuticals (SNDX)
Comments (0)
Please sign in to join the discussion